Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

A novel fluorescence-based functional assay for human OATP1A2 and OATP1C1 identifies interaction between third generation P-gp inhibitors and OATP1A2.

Bakos É, Német O, Patik I, Kucsma N, Várady G, Szakács G, Özvegy-Laczka C.

FEBS J. 2019 Nov 26. doi: 10.1111/febs.15156. [Epub ahead of print]

PMID:
31770475
2.

Circulating Picomolar Levels of CCL2 Downregulate Ongoing Chronic Experimental Autoimmune Encephalomyelitis by Induction of Regulatory Mechanisms.

Kaushansky N, Bakos E, Becker-Herman S, Shachar I, Ben-Nun A.

J Immunol. 2019 Oct 1;203(7):1857-1866. doi: 10.4049/jimmunol.1900424. Epub 2019 Sep 4.

PMID:
31484731
3.

Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1.

Patik I, Székely V, Német O, Szepesi Á, Kucsma N, Várady G, Szakács G, Bakos É, Özvegy-Laczka C.

Sci Rep. 2018 Feb 8;8(1):2630. doi: 10.1038/s41598-018-20815-1.

4.

Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography.

Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, Stanek J, Nics L, Klebermass EM, Poschner S, Jäger W, Patik I, Bakos É, Szakács G, Wadsak W, Hacker M, Zeitlinger M, Langer O.

Clin Pharmacol Ther. 2018 Jul;104(1):139-147. doi: 10.1002/cpt.888. Epub 2017 Nov 3.

5.

T Cells Regulate Peripheral Naive Mature B Cell Survival by Cell-Cell Contact Mediated through SLAMF6 and SAP.

Radomir L, Cohen S, Kramer MP, Bakos E, Lewinsky H, Barak A, Porat Z, Bucala R, Stepensky P, Becker-Herman S, Shachar I.

J Immunol. 2017 Oct 15;199(8):2745-2757. doi: 10.4049/jimmunol.1700557. Epub 2017 Sep 13.

6.

CCR2 Regulates the Immune Response by Modulating the Interconversion and Function of Effector and Regulatory T Cells.

Bakos E, Thaiss CA, Kramer MP, Cohen S, Radomir L, Orr I, Kaushansky N, Ben-Nun A, Becker-Herman S, Shachar I.

J Immunol. 2017 Jun 15;198(12):4659-4671. doi: 10.4049/jimmunol.1601458. Epub 2017 May 15.

7.

The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.

Wakim J, Arman E, Becker-Herman S, Kramer MP, Bakos E, Shachar I, Elson A.

Oncogene. 2017 Jun 29;36(26):3686-3694. doi: 10.1038/onc.2016.523. Epub 2017 Feb 6.

PMID:
28166196
8.

CD151 Regulates T-Cell Migration in Health and Inflammatory Bowel Disease.

Zelman-Toister E, Bakos E, Cohen S, Zigmond E, Shezen E, Grabovsky V, Sagiv A, Hart G, Kaushansky N, Ben-Nun A, Maharshak N, Sonnenberg A, Alon R, Becker-Herman S, Shachar I.

Inflamm Bowel Dis. 2016 Feb;22(2):257-67. doi: 10.1097/MIB.0000000000000621.

PMID:
26529559
9.

c-Kit is suppressed in human colon cancer tissue and contributes to L1-mediated metastasis.

Gavert N, Shvab A, Sheffer M, Ben-Shmuel A, Haase G, Bakos E, Domany E, Ben-Ze'ev A.

Cancer Res. 2013 Sep 15;73(18):5754-63. doi: 10.1158/0008-5472.CAN-13-0576. Epub 2013 Sep 5.

10.

The high turnover Drosophila multidrug resistance-associated protein shares the biochemical features of its human orthologues.

Szeri F, Iliás A, Pomozi V, Robinow S, Bakos E, Váradi A.

Biochim Biophys Acta. 2009 Feb;1788(2):402-9. doi: 10.1016/j.bbamem.2008.11.007. Epub 2008 Nov 20.

11.

Membrane topology of the human multidrug resistance-associated protein (MRP) and its homologs.

Váradi A, Tusnády GE, Bakos E, Sarkadi B.

Cytotechnology. 1998 Sep;27(1-3):71-9. doi: 10.1023/A:1008031914247. No abstract available.

12.

Conversions in laparoscopic cholecystectomy.

Bakos E, Bakos M, Dubaj M, Prekop I, Jankovic T.

Bratisl Lek Listy. 2008;109(7):317-9.

PMID:
18792487
13.

Atypical cyst of the right ductus hepaticus.

Prekop I, Sevcik L, Jakubicka J, Bakos E, Bakos M, Durcansky D.

Bratisl Lek Listy. 2007;108(10-11):474-6.

PMID:
18306731
14.

Miniinvasive treatment of pericardial effusions.

Bakos E, Bakos M, Dubaj M, Poliacik P.

Bratisl Lek Listy. 2007;108(7):324-6.

PMID:
17972553
15.

Enterovesical fistulas in Crohn's disease.

Pechan J, Pindak D, Lutter I, Weibl P, Bernadic M, Bakos E.

Bratisl Lek Listy. 2007;108(7):307-8.

PMID:
17972548
16.

State-dependent inhibition of cystic fibrosis transmembrane conductance regulator chloride channels by a novel peptide toxin.

Fuller MD, Thompson CH, Zhang ZR, Freeman CS, Schay E, Szakács G, Bakos E, Sarkadi B, McMaster D, French RJ, Pohl J, Kubanek J, McCarty NA.

J Biol Chem. 2007 Dec 28;282(52):37545-55. Epub 2007 Oct 19.

17.

[Quadruparesis as a complication of acute pancreatitis--case report].

Bircak J, Bakos E, Dubaj M, Strmen J, Brozman M.

Rozhl Chir. 2007 Jul;86(7):343-5. Slovak.

PMID:
17879709
18.

[Choledochal cyst complication of pregnancy].

Bakos E, Mlyncek M, Dubaj M, Durcanský D, Bakos M, Korcek J, Jankovic T.

Rozhl Chir. 2007 May;86(5):236-40. Slovak.

PMID:
17634012
19.

[Acute intestinal ischaemia].

Bakos E, Osuský M, Korcek J, Bakos M.

Rozhl Chir. 2007 Apr;86(4):184-7. Slovak.

PMID:
17626460
20.

Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1).

Bakos E, Homolya L.

Pflugers Arch. 2007 Feb;453(5):621-41. Epub 2006 Dec 23. Review.

PMID:
17187268
21.

Combined parasacral, vaginal and endorectal approach in surgical treatment of giant rectocele.

Korcek J, Bakos E, Farkas A.

Acta Chir Iugosl. 2006;53(2):43-9.

PMID:
17139884
22.

[Postoperative adhesions, the everlasting topical subject].

Bakos E, Korcek J, Dubaj M, Osuský M, Bakos M.

Rozhl Chir. 2006 Mar;85(3):134-8. Slovak.

PMID:
16689145
23.

[Internal hernias--uncommon causes of the status ileosus].

Bakos E, Korcek J, Dubaj M, Lazorisák A, Bakos M.

Rozhl Chir. 2006 Feb;85(2):93-7. Slovak.

PMID:
16626020
24.

[Primary tumors of the duodenum and the small intestine in our clinical study subjects over a ten-year period].

Dubaj M, Bakos E, Galko J, Lazorisák A.

Rozhl Chir. 2006 Feb;85(2):90-2. Slovak.

PMID:
16626019
25.

Parasacral and perineal sphincteroplasty.

Korcek J, Bakos E, Klobusicky P.

Tech Coloproctol. 2005 Dec;9(3):250-1. No abstract available.

PMID:
16370039
26.

The role of the conserved glycines of ATP-binding cassette signature motifs of MRP1 in the communication between the substrate-binding site and the catalytic centers.

Szentpétery Z, Kern A, Liliom K, Sarkadi B, Váradi A, Bakos E.

J Biol Chem. 2004 Oct 1;279(40):41670-8. Epub 2004 Jul 12.

27.

Functional studies on the MRP1 multidrug transporter: characterization of ABC-signature mutant variants.

Szentpétery Z, Sarkadi B, Bakos E, Váradi A.

Anticancer Res. 2004 Mar-Apr;24(2A):449-55.

28.

Nucleotides and transported substrates modulate different steps of the ATPase catalytic cycle of MRP1 multidrug transporter.

Kern A, Szentpétery Z, Liliom K, Bakos E, Sarkadi B, Váradi A.

Biochem J. 2004 Jun 1;380(Pt 2):549-60.

29.

Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions.

Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B.

J Biol Chem. 2003 Jun 27;278(26):23529-37. Epub 2003 Apr 19.

30.

The role of multidrug transporters in drug availability, metabolism and toxicity.

Bodó A, Bakos E, Szeri F, Váradi A, Sarkadi B.

Toxicol Lett. 2003 Apr 11;140-141:133-43. Review.

PMID:
12676459
31.

C-terminal phosphorylation of MRP2 modulates its interaction with PDZ proteins.

Hegedüs T, Sessler T, Scott R, Thelin W, Bakos E, Váradi A, Szabó K, Homolya L, Milgram SL, Sarkadi B.

Biochem Biophys Res Commun. 2003 Mar 14;302(3):454-61.

PMID:
12615054
32.

Role of the N-terminal transmembrane region of the multidrug resistance protein MRP2 in routing to the apical membrane in MDCKII cells.

Fernández SB, Holló Z, Kern A, Bakos E, Fischer PA, Borst P, Evers R.

J Biol Chem. 2002 Aug 23;277(34):31048-55. Epub 2002 Jun 11.

33.

P glycoprotein and the mechanism of multidrug resistance.

Váradi A, Szakács G, Bakos E, Sarkadi B.

Novartis Found Symp. 2002;243:54-65; discussion 65-8, 180-5. Review.

PMID:
11990782
34.

Role of glycine-534 and glycine-1179 of human multidrug resistance protein (MDR1) in drug-mediated control of ATP hydrolysis.

Szakács G, Ozvegy C, Bakos E, Sarkadi B, Váradi A.

Biochem J. 2001 May 15;356(Pt 1):71-5.

35.

Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1).

Bakos E, Evers R, Calenda G, Tusnády GE, Szakács G, Váradi A, Sarkadi B.

J Cell Sci. 2000 Dec;113 Pt 24:4451-61.

36.

Transition-state formation in ATPase-negative mutants of human MDR1 protein.

Szakács G, Ozvegy C, Bakos E, Sarkadi B, Váradi A.

Biochem Biophys Res Commun. 2000 Oct 5;276(3):1314-9.

PMID:
11027628
37.

Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions.

Bakos E, Evers R, Sinkó E, Váradi A, Borst P, Sarkadi B.

Mol Pharmacol. 2000 Apr;57(4):760-8.

PMID:
10727523
38.

Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: evidence for an in vivo role in cervical lesions.

Zehbe I, Rätsch A, Alunni-Fabbroni M, Burzlaff A, Bakos E, Dürst M, Wilander E, Tommasino M.

Oncogene. 1999 Apr 1;18(13):2201-11.

39.

Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain.

Bakos E, Evers R, Szakács G, Tusnády GE, Welker E, Szabó K, de Haas M, van Deemter L, Borst P, Váradi A, Sarkadi B.

J Biol Chem. 1998 Nov 27;273(48):32167-75.

40.

Babesia equi field isolates cultured from horse blood using a microcentrifuge method.

Holman PJ, Becu T, Bakos E, Polledo G, Cruz D, Wagner GG.

J Parasitol. 1998 Aug;84(4):696-9.

PMID:
9714196
41.

Identification of novel molecular markers which correlate with HPV-induced tumor progression.

Nees M, van Wijngaarden E, Bakos E, Schneider A, Dürst M.

Oncogene. 1998 May 14;16(19):2447-58.

42.

Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity.

Szabó K, Bakos E, Welker E, Müller M, Goodfellow HR, Higgins CF, Váradi A, Sarkadi B.

J Biol Chem. 1997 Sep 12;272(37):23165-71.

43.

Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region.

Bakos E, Klein I, Welker E, Szabó K, Müller M, Sarkadi B, Váradi A.

Biochem J. 1997 May 1;323 ( Pt 3):777-83.

44.

Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters.

Tusnády GE, Bakos E, Váradi A, Sarkadi B.

FEBS Lett. 1997 Jan 27;402(1):1-3. Review.

45.

Membrane topology and glycosylation of the human multidrug resistance-associated protein.

Bakos E, Hegedüs T, Holló Z, Welker E, Tusnády GE, Zaman GJ, Flens MJ, Váradi A, Sarkadi B.

J Biol Chem. 1996 May 24;271(21):12322-6.

46.

Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein.

Müller M, Bakos E, Welker E, Váradi A, Germann UA, Gottesman MM, Morse BS, Roninson IB, Sarkadi B.

J Biol Chem. 1996 Jan 26;271(4):1877-83.

47.
48.
49.

[A case of chagas infection caused by an atypical strain of Trypanosoma cruzi in a newborn infant].

de Storni P, Bakos E, Bustamante A, Vanioff JA.

Medicina (B Aires). 1984;44(3):287-91. Spanish. No abstract available.

PMID:
6443628
50.

[Experience with Blackburn's method of parenteral nutrition].

Kleinová E, Kratochvíl M, Bakos E.

Rozhl Chir. 1982 Aug;61(8):559-65. Slovak. No abstract available.

PMID:
6813977

Supplemental Content

Support Center